Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alnylam Holding Co.

www.alnylam.com

Latest From Alnylam Holding Co.

Keeping Track: First RMAT Approval On The Horizon; Big Weeks For Merck, Lilly And Celgene

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation

Key Drug Launches To Plan For In 2019

Around three dozen key late-stage products could reach their first markets in 2019, according to a recent report from Informa Pharma's Biomedtracker. Company execs may need to plan for the disruptive potential of this group of new medicines on established markets and standards of care.

Approvals Launches

Alnylam's Onpattro Carries Narrower hATTR Indication Without Cardiac Data

US FDA still appears to be open, if not optimistic, about path towards broader label for patisiran, the first-of-its-kind targeted RNA-based therapy. 
Approvals Rare Diseases

Keeping Track: Poteligeo, Onpattro, Galafold And Annovera Approved; Selinexor Submitted

The latest drug development news and highlights from our US FDA Performance Tracker.
Drug Review Regulation
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Alnylam Holding Co.
  • Senior Management
  • John Maraganore, PhD, Pres. & CEO
    Nagesh Mahanthappa, PhD, Dir. Corp. Dev.
    Barry Greene, COO
    Muthiah Manoharan, PhD, VP, Drug Discovery
    Victor Kotelianski, MD, PhD, VP, R&D
  • Contact Info
  • Alnylam Holding Co.
    Phone: (617) 252-0700
    790 Memorial Dr., Ste. 202
    Cambridge, MA 02139
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register